MA50374A - ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS - Google Patents

ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS

Info

Publication number
MA50374A
MA50374A MA050374A MA50374A MA50374A MA 50374 A MA50374 A MA 50374A MA 050374 A MA050374 A MA 050374A MA 50374 A MA50374 A MA 50374A MA 50374 A MA50374 A MA 50374A
Authority
MA
Morocco
Prior art keywords
binding
antigen
bispecific antibodies
present
treatment
Prior art date
Application number
MA050374A
Other languages
French (fr)
Other versions
MA50374B1 (en
Inventor
Samuel Davis
Jessica R Kirshner
Eric Smith
Gavin Thurston
Bindu Varghese
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA50374A publication Critical patent/MA50374A/en
Publication of MA50374B1 publication Critical patent/MA50374B1/en

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention propose des anticorps bispécifiques qui se lient au cd3 et aux antigènes tumoraux et des procédés d'utilisation de ceux-ci. Selon certains modes de réalisation, les anticorps bispécifiques de l'invention présentent des fonctions effectrices réduites et ont un profil de liaison unique vis-à-vis des récepteurs fcy. Les anticorps bispécifiques sont conçus pour induire efficacement la destruction des cellules tumorales par les lymphocytes t. Selon certains modes de réalisation, la présente invention propose des molécules bispécifiques de liaison à l'antigène comprenant un premier domaine de liaison à l'antigène qui se lie spécifiquement au cd3 humain, une seconde molécule de liaison à l'antigène qui se lie spécifiquement au cd20 humain, et un domaine fc qui lie les récepteurs fcy avec un motif de reliure. Dans certains modes de réalisation, les molécules de liaison d'antigène bispécifiques de la présente invention sont capables d'inhiber la croissance de cellules b ou de tumeurs de mélanome exprimant cd20. Les anticorps bispécifiques de l'invention sont utiles pour le traitement de divers cancers ainsi que d'autres maladies et troubles liés au cd20.The present invention provides bispecific antibodies which bind to cd3 and tumor antigens and methods of use thereof. According to some embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile towards fcy receptors. Bispecific antibodies are designed to efficiently induce destruction of tumor cells by t lymphocytes. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain which binds specifically to human cd3, a second antigen-binding molecule which binds specifically to human cd20, and an fc domain that binds fcy receptors with a binding motif. In certain embodiments, the bispecific antigen binding molecules of the present invention are capable of inhibiting the growth of b cells or melanoma tumors expressing cd20. The bispecific antibodies of the invention are useful for the treatment of various cancers as well as other diseases and disorders related to cd20.

MA50374A 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors MA50374B1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201461955663P 2014-03-19 2014-03-19
US201461981641P 2014-04-18 2014-04-18
US201462007385P 2014-06-03 2014-06-03
US201462033460P 2014-08-05 2014-08-05

Publications (2)

Publication Number Publication Date
MA50374A true MA50374A (en) 2020-01-15
MA50374B1 MA50374B1 (en) 2021-06-30

Family

ID=58699943

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50374A MA50374B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors
MA39751A MA39751B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA39751A MA39751B1 (en) 2014-03-19 2015-03-18 Antibody compositions for the treatment of tumors

Country Status (3)

Country Link
AR (1) AR099798A1 (en)
HR (1) HRP20210615T1 (en)
MA (2) MA50374B1 (en)

Also Published As

Publication number Publication date
AR099798A1 (en) 2016-08-17
MA39751B1 (en) 2019-11-29
MA50374B1 (en) 2021-06-30
HRP20210615T1 (en) 2021-05-28

Similar Documents

Publication Publication Date Title
MA42542B1 (en) Molecules Binding to pd-1 and Corresponding Methods of Use
EA201691858A1 (en) ANTIBODY COMPOSITIONS FOR TREATMENT OF TUMORS
MX2019013033A (en) Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof.
ZA201803079B (en) Anti-dr5 antibodies and methods of use thereof
CA2886433C (en) Human monoclonal anti-pd-l1 antibodies and methods of use
EA201792657A1 (en) Binding LAG-3 MOLECULES AND METHODS OF THEIR APPLICATION
MA42935B1 (en) Optimized anti-cd3 bispecific antibodies and their uses
TN2019000294A1 (en) Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MA40041A (en) ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE
MX2013012201A (en) Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies.
MA33402B1 (en) COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES
EA201400390A1 (en) ANTIBODIES TO TL1A AND THEIR APPLICATION
PH12020551661A1 (en) Anti-pd-l1 antibody and use thereof
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
MX2021005048A (en) Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof.
MX2022009915A (en) Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof.
EP4249511A3 (en) Anti-pd-l1/anti-lag3 bispecific antibodies and uses thereof
EA201791691A1 (en) SINGLE-DOMAIN ANTIBODIES DIRECTED TO CD1d
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
MA50374B1 (en) Antibody compositions for the treatment of tumors
MA47137B1 (en) Pd-1 and lag-3 binding molecules and their methods of use
MX2022001882A (en) 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40.
MX2021003756A (en) Pharmaceutical compositions comprising bispecific anti-cd37 antibodies.
MA37998A1 (en) Anti-cd3 antibodies, bispecific antigen binding molecules that bind to cd3 and cd20, and their uses
WO2021113307A3 (en) Antibodies against pd-l1 and methods of use thereof